MedPath

Metabolomic study in head and neck cancer patients receiving concurrent chemoradiotherapy (CCRT) and Hydrogen gas inhalation: Pilot study

Phase 2
Conditions
The serum metabolome in 2 groups of locally advanced head and neck cancer patients who will be treated with CCRT plus H2 gas inhalation versus CCRT alone.
Metabolome, Metabolomic, Hydrogen gas, Hydrogen gas Inhalation, Concurrent chemoradiotherapy, Locally advanced head and neck cancer
Registration Number
TCTR20240515006
Lead Sponsor
Faculty of Medicine, Chiang Mai University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Enrolling by invitation
Sex
All
Target Recruitment
20
Inclusion Criteria

Loco-regional advanced stage HNC.
Histologically-proven diagnosis of HNC.
Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
Able to provide informed consent.

Exclusion Criteria

Distant metastasis or locoregional recurrence disease.
Contraindications to RT or chemotherapy or Hydrogen gas inhalation.
Previous head and neck irradiation.
Patients with tracheostomy tube.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Metabolome Before and end of CCRT. The proton NMR spectrum will be recorded and acquired using a Bruker AVANCE 500 MHz instrument.
Secondary Outcome Measures
NameTimeMethod
Safety of hydrogen gas inhalation During CCRT Descriptive
© Copyright 2025. All Rights Reserved by MedPath